USFDA completes inspection of Natco's Vizag Formulation facility

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the completion of a regulatory inspection from the United States Food and Drug Administration (USFDA) for its Formulation facility in Ramky SEZ, near Visakhapatnam (Vizag), India, which was conducted during the period 30th January, 2023 to 3rd February, 2023.

At the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure. The Company is confident of addressing all observations within the stipulated time.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 528.20 as compared to the previous close of Rs. 522.75. The total number of shares traded during the day was 8202 in over 1163 trades.

The stock hit an intraday high of Rs. 536.40 and intraday low of 522.65. The net turnover during the day was Rs. 4342056.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Inspection USFDA FormulationFacility RamkySEZ Vizag